Providing More Guidance and Agency Experts Among FDA Combination Products Priorities
Last year FDA released its Combination Products Review, Intercenter Consult Process Study Report, an eight-page document that made recommendations around areas that the agency needs to address in modernizing the combination products review program.
“As technologies advance across multiple fields, the distinctions that previously allowed combination products to be neatly categorized by FDA’s medical product centers are blurring or even vanishing.” – Nina Hunter, Ph.D. and Robert Califf, M.D., FDA
Among key priorities from last year’s report were providing more guidance for product review, simplifying data access and sharing for internal agency staff, and improving internal standard operating procedures related to premarket reviews and compliance activities. Last week FDA outlined next steps to the commitments it made last year including:
- Finalize Guidance on Human Factors, CGMP, Post approval Modifications and Final Rule on Postmarket Safety Reporting
- Issue guidance on Pre-RFD progress for requesting early feedback on combination products
- All staff involved with combination products review to be trained on the same process and use some request form to monitor submissions and consult requests
- Provide key contacts in the Office of Combination Products and other agency centers for product review
- Draft and implement staff manual guides to improve other areas of agency review
Related Articles
-
With the goal of acting as a single agency, FDA’s OCP has several activities planned for this year.
-
Susan Alpert, principal of SFA Consulting, explains the role of clinical evidence for combination products and the complexities at play.
-
The agency calls out specific devices that should include human factors data in premarket submissions, along with recommendations for combination products.
-
What are the challenges faced by OCP?
-
The creation of the Office of Combination Products more than a decade ago may have been a big step forward, but frustrations surrounding policy-making and coordination between CDRH, CDER and CBER remain.
-
The agency is creating a virtual center of excellence to expedite the development of combination products.
-
Combination products are a major growth area for life science companies and in the future, many companies have or will have combination products in their portfolio. Combination products are made of drug, device and/or biologics constituent parts. Each constituent part…
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.